{"ticker": {"uuid": "c7a32f14-5cb5-4c91-8f75-c30a604b5c77", "symbol": "300199", "name": "Hybio Pharmaceutical Co., Ltd.", "exchange": "SHZ", "country": "CN", "sector": "Healthcare", "industry": "Drug Manufacturers - Specialty & Generic"}, "articles": [{"title": "Hybio's generic weight-loss drug set for FDA review", "summary": "", "url": "https://news.google.com/rss/articles/CBMixwFBVV95cUxPUGFVTDQ5ZGxxUFZWam9UQm1mTVRpcnJ6M3FSSGRwdDQ3el92SVdENnlET3hnejhCN3ZrVW9zckNIUHkxSVNKUmFlNnNUak9JUVNrVmtKVU1JVWdXX0NYaFA1RXVOUThuSDFpVVNLTlpfaV9GWnFTT0VBOGVtRng5T25EbXVKTmdvUjcxU3YzSkQ5Z2ZSNDlTZWEtVzFwTVV1dDRMZXlxYzQyYnBTN1d3U3ZTbFlSTFFkajlLbWtlN0pUcjFhUHVZ?oc=5", "source_name": "Reuters", "published_at": "2026-06-30T07:00:00+00:00", "published_display": "30 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Despite Hybio Pharmaceutical's share price surge, its high P/S ratio and declining medium-term revenue could risk shareholders' investments. If the P/S aligns with recent negative growth rates, investors may face disappointment.", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPNm1CcDJqRjFMSDhwQ0stMDVoSTk3WWJPQVhkemtrZVplWFhiT2M0UVVKMXZoWGdtR3JYMHI4YlFIemowM051NVpZOUllNlpGYVlkRVhabXl5MUZQa1NRUUVVOHR2WWRla2RCU3Z1akFXMEhjUk5pVVNzNndwSnd5R1ZsbTctWmJhVmt3NkxmZS1oSERqZ0NxR2swSGdSVkJtQTllcDkyMVpvWFlMZjMxNnU1NA?oc=5", "source_name": "Moomoo", "published_at": "2024-03-16T07:00:00+00:00", "published_display": "16 Mar 2024 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "Hybio's generic weight-loss drug set for FDA review", "summary": "", "url": "https://news.google.com/rss/articles/CBMixwFBVV95cUxPUGFVTDQ5ZGxxUFZWam9UQm1mTVRpcnJ6M3FSSGRwdDQ3el92SVdENnlET3hnejhCN3ZrVW9zckNIUHkxSVNKUmFlNnNUak9JUVNrVmtKVU1JVWdXX0NYaFA1RXVOUThuSDFpVVNLTlpfaV9GWnFTT0VBOGVtRng5T25EbXVKTmdvUjcxU3YzSkQ5Z2ZSNDlTZWEtVzFwTVV1dDRMZXlxYzQyYnBTN1d3U3ZTbFlSTFFkajlLbWtlN0pUcjFhUHVZ?oc=5", "source_name": "Reuters", "published_at": "2026-06-30T07:00:00+00:00", "published_display": "30 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Despite Hybio Pharmaceutical's share price surge, its high P/S ratio and declining medium-term revenue could risk shareholders' investments. If the P/S aligns with recent negative growth rates, investors may face disappointment.", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPNm1CcDJqRjFMSDhwQ0stMDVoSTk3WWJPQVhkemtrZVplWFhiT2M0UVVKMXZoWGdtR3JYMHI4YlFIemowM051NVpZOUllNlpGYVlkRVhabXl5MUZQa1NRUUVVOHR2WWRla2RCU3Z1akFXMEhjUk5pVVNzNndwSnd5R1ZsbTctWmJhVmt3NkxmZS1oSERqZ0NxR2swSGdSVkJtQTllcDkyMVpvWFlMZjMxNnU1NA?oc=5", "source_name": "Moomoo", "published_at": "2024-03-16T07:00:00+00:00", "published_display": "16 Mar 2024 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [], "sector": []}, "total_fetched": 45, "total_relevant": 2, "sentiment_summary": {"positive": 0, "negative": 0, "neutral": 2, "score": 50, "total": 2, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 62, "events": [{"event": "general", "label": "Market update", "weight": 0.9, "count": 1}, {"event": "earnings", "label": "Earnings", "weight": 0.55, "count": 1}], "positive_events": 0, "negative_events": 0}, "market_context": {"has_market_context": true, "latest_close": 21.44, "latest_week": "2026-07-17", "one_week_move": -15.7, "four_week_move": -2.5, "twelve_week_move": -1.4, "trend_signal": "1", "trend_label": "Trend active", "trend_tone": "positive", "market_dynamics": 0.643744, "market_dynamics_buy_signal": false, "relative_strength": 1.252968, "fair_value_gap": 39.8, "fair_value_label": "Materially above fair value", "fair_value_tone": "negative", "expectation_direction": "negative", "expectation_probability": 44.6323, "reaction_label": "Price reacting lower", "reaction_tone": "negative", "market_sentence": "-15.7% over one week, -2.5% over four weeks, trend active, and materially above fair value."}, "interpretation": {"label": "Price moving ahead of tone", "tone": "negative", "classification": "price_leads_news", "summary": "Price is moving more forcefully than the current news tone suggests.", "confidence": 52, "badges": [], "opportunities": [], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Reuters", "count": 1}, {"label": "Moomoo", "count": 1}], "tiers": [{"label": "Direct company coverage", "count": 2}, {"label": "Industry context", "count": 0}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 1}, {"label": "Earnings", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "50/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Price moving ahead of tone", "tone": "negative", "text": "Price is moving more forcefully than the current news tone suggests."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "62/100 classification confidence."}, {"label": "Company focus", "value": "2", "tone": "neutral", "text": "directly relevant articles"}, {"label": "Source quality", "value": "1", "tone": "positive", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend active", "tone": "positive", "text": "-15.7% over one week, -2.5% over four weeks, trend active, and materially above fair value."}, {"label": "Latest direct headline", "value": "Neutral", "tone": "neutral", "text": "Hybio's generic weight-loss drug set for FDA review"}], "updated_at": "2026-07-23T02:34:21.079496+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}